

VIA EFS
Date of Deposit: November 21, 2011

Docket No.: 16534-526002US
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Michael P. Draper et al.

Application No.: 10/692,563

Confirmation No.: 9127

Filed: October 24, 2003

Art Unit: 1628

For: Substituted Tetracycline Compounds For The
Treatment Of Malaria

Examiner: S. N. Qazi

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

STATEMENT OF SUBSTANCE OF INTERVIEW

Applicants submit a statement of the substance of the telephonic interview held between Christopher E. Olson and the Examiner on August 11, 2011.

During the interview, Applicants' counsel and the Examiner discussed US Patent 6,642,270 which contains heterocyclic-substituted tetracycline compounds. Unlike the compounds in US Patent 6,642,270, the instant claims relate to compounds having furanyl or thienyl substituents, e.g., unsaturated heterocycles directly attached to tetracycline core.

Applicants also confirmed that the substitute specification filed on June 1, 2011, was filed to enlarge compound structures for publication purposes.

No other pertinent matters were discussed.

No fees are believed due. However, the Commissioner is authorized to charge any fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0311, Reference No. 28682-506001US. If there are any questions regarding this Statement, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Dated: November 21, 2011

Respectfully submitted,

By 

Heidi A. Erlacher, J.D., Ph.D.

Registration No.: 45,409

MINTZ LEVIN COHN FERRIS GLOVSKY
AND POPEO, P.C.

One Financial Center
Boston, Massachusetts 02111
(617) 542-6000
Attorney for Applicant